Myeloid Therapeutics, Inc.

Batu Biologics

Samuel C Wagner

Amit N Patel

Santosh Kesari

Boris Minev

Thomas E Ichim

Julia S Szymanski

Andy J Kim

Dimitri N Theofilopoulos

Brandon R Dolan

Naseem Ajili

The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.

Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer

The current application teaches methods and compositions useful for the treatment of cancer through administration of an antioxidant together with an immune stimulator at concentrations sufficient to augment antitumor immunity while simultaneously preventing inhibition of T cell function as a result of tumor secreted oxidative stress. Compositions such as toll like receptor agonists in combination with antioxidants are disclosed. In further embodiments, the application teaches the use of antioxidants to prevent immunotherapy associated oxidative stress, of which, one manifestation is vascular leak syndrome. In one specific embodiment, the application teaches the use of intravenous ascorbic acid as a means of reducing IL-2 associated toxicity.

Use of antioxidants as an adjuvant to immune stimulators to augment tumor immunity and prevent toxicity associated with oxidative stress

Growing community of inventors

San Diego, CA, United States of America

Samuel C Wagner